CervoMed Inc. (CRVO) - Total Assets
Based on the latest financial reports, CervoMed Inc. (CRVO) holds total assets worth $15.11 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can CervoMed Inc. service its debt to assess how comfortably operating cash covers total debt obligations.
CervoMed Inc. - Total Assets Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s total assets have evolved over time, based on quarterly financial data. See CRVO net asset value for net asset value and shareholders' equity analysis.
CervoMed Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
CervoMed Inc.'s total assets of $15.11 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.2% |
| Accounts Receivable | $426.99K | 1.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRVO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CervoMed Inc.'s current assets represent 96.4% of total assets in 2025, an increase from 93.0% in 1998.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 1.8% of total assets.
CervoMed Inc. Competitors by Total Assets
Key competitors of CervoMed Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
CervoMed Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.65 | 9.78 | 20.88 |
| Quick Ratio | 6.65 | 9.78 | 20.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.84 Million | $34.63 Million | $41.76 Million |
CervoMed Inc. - Advanced Valuation Insights
This section examines the relationship between CervoMed Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.96 |
| Latest Market Cap to Assets Ratio | 0.97 |
| Asset Growth Rate (YoY) | -45.7% |
| Total Assets | $23.40 Million |
| Market Capitalization | $22.59 Million USD |
Valuation Analysis
Near Book Valuation: The market values CervoMed Inc.'s assets close to their book value (0.97x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: CervoMed Inc.'s assets decreased by 45.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CervoMed Inc. (1998–2025)
The table below shows the annual total assets of CervoMed Inc. from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $23.40 Million | -45.69% |
| 2024-12-31 | $43.08 Million | +332.00% |
| 2023-12-31 | $9.97 Million | +139.86% |
| 2022-12-31 | $4.16 Million | -89.01% |
| 2021-12-31 | $37.84 Million | +36.46% |
| 2020-12-31 | $27.73 Million | +14.21% |
| 2019-12-31 | $24.28 Million | +33.38% |
| 2018-12-31 | $18.20 Million | -30.38% |
| 2017-12-31 | $26.15 Million | +49.54% |
| 2016-12-31 | $17.48 Million | +668.01% |
| 2015-12-31 | $2.28 Million | -94.68% |
| 2014-12-31 | $42.78 Million | +133.20% |
| 2013-12-31 | $18.34 Million | +649.87% |
| 2012-12-31 | $2.45 Million | -33.41% |
| 2011-12-31 | $3.67 Million | -34.11% |
| 2010-12-31 | $5.58 Million | +30.18% |
| 2009-12-31 | $4.28 Million | -20.13% |
| 2008-12-31 | $5.36 Million | -20.00% |
| 2007-12-31 | $6.70 Million | -69.78% |
| 1999-12-31 | $22.18 Million | +19.90% |
| 1998-12-31 | $18.50 Million | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more